Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

Our new manuscript “Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition” is now available in Clinical Proteomics.

Our research identified potential protein candidates for a blood-based prognostic signature of response to crizotinib in NSCLC patients harboring ALK fusion. https://doi.org/10.1186/s12014-020-9269-6 (Feb 2020)

Publication: https://www.exactis.ca/2020/02/07/discovery-of-a-putative-blood-based-protein-signature-associated-with-response-to-alk-tyrosine-kinase-inhibition/